Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGON 
CG Oncology, Inc. Common stock (CGON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: CGON (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $68.08
1 Year Target Price $68.08
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.32% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.24B USD | Price to earnings Ratio - | 1Y Target Price 68.08 |
Price to earnings Ratio - | 1Y Target Price 68.08 | ||
Volume (30-day avg) 10 | Beta - | 52 Weeks Range 14.80 - 45.56 | Updated Date 10/31/2025 |
52 Weeks Range 14.80 - 45.56 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -28546.1% |
Management Effectiveness
Return on Assets (TTM) -12.85% | Return on Equity (TTM) -16.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2378789340 | Price to Sales(TTM) 5877.01 |
Enterprise Value 2378789340 | Price to Sales(TTM) 5877.01 | ||
Enterprise Value to Revenue 4317.22 | Enterprise Value to EBITDA - | Shares Outstanding 76247581 | Shares Floating 61016364 |
Shares Outstanding 76247581 | Shares Floating 61016364 | ||
Percent Insiders 3.15 | Percent Institutions 112.92 |
Upturn AI SWOT
CG Oncology, Inc. Common stock
Company Overview
History and Background
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing oncolytic immunotherapies for patients with bladder cancer. Founded to address unmet needs in bladder cancer treatment, CG Oncology has advanced into late-stage clinical trials with its lead candidate, cretostimogene grenadenorepvec.
Core Business Areas
- Oncolytic Immunotherapy Development: Focuses on developing and commercializing cretostimogene grenadenorepvec for bladder cancer and potentially other solid tumors.
- Clinical Trials and Research: Conducting clinical trials to evaluate the safety and efficacy of its immunotherapy candidates.
- Manufacturing and Supply Chain: Establishing manufacturing capabilities to support clinical trials and future commercialization.
Leadership and Structure
Arthur Kuan (CEO), Mark Efroymson (CFO). The company structure consists of departments focused on research & development, clinical operations, manufacturing, and commercial strategy.
Top Products and Market Share
Key Offerings
- Cretostimogene Grenadenorepvec: An oncolytic immunotherapy in late-stage clinical development for non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guu00e9rin (BCG). Market share is currently 0% as the drug is not yet approved. Competitors include Merck (Keytruda) in BCG-unresponsive NMIBC and other therapies like gemcitabine and docetaxel.
Market Dynamics
Industry Overview
The oncology market is characterized by intense competition and rapid innovation, with a growing emphasis on immunotherapies and targeted therapies. The bladder cancer treatment market is significant, driven by an aging population and environmental risk factors.
Positioning
CG Oncology is positioned as a developer of novel oncolytic immunotherapies, targeting a specific unmet need in BCG-unresponsive NMIBC. Its competitive advantage lies in its differentiated mechanism of action and potentially improved efficacy and safety profile.
Total Addressable Market (TAM)
The TAM for bladder cancer treatment is estimated to be in the billions of dollars. CG Oncology is targeting a specific segment within this TAM, focusing on BCG-unresponsive NMIBC. Its positioning allows it to capture a significant share of this segment if cretostimogene grenadenorepvec is approved.
Upturn SWOT Analysis
Strengths
- Late-stage clinical asset (Cretostimogene)
- Targeting unmet need in BCG-unresponsive NMIBC
- Experienced management team
- Novel oncolytic immunotherapy approach
Weaknesses
- Reliance on a single lead candidate
- High regulatory and clinical trial risk
- Lack of commercialized products
- Potential manufacturing challenges
Opportunities
- Expansion into other solid tumor indications
- Partnerships with pharmaceutical companies
- Potential for accelerated regulatory approval
- Positive clinical trial results
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- MRK
- BIIB
- AGEN
Competitive Landscape
CG Oncology competes with established pharmaceutical companies in the bladder cancer treatment market. Its competitive advantage lies in its novel oncolytic immunotherapy approach, potentially offering improved efficacy and safety compared to existing therapies. However, it faces challenges related to clinical trial risk and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the advancement of cretostimogene grenadenorepvec through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of cretostimogene grenadenorepvec. Analyst estimates vary depending on the likelihood of approval and market penetration.
Recent Initiatives: Recent initiatives include enrolling patients in the ongoing Phase 3 clinical trial of cretostimogene grenadenorepvec and expanding manufacturing capacity.
Summary
CG Oncology is a development-stage biopharmaceutical company focused on bladder cancer treatment with a promising late-stage asset. Its success hinges on the clinical trial outcomes and regulatory approval of its lead candidate. The company's innovative oncolytic immunotherapy approach offers a competitive advantage, but it faces inherent risks in drug development and competition from established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CG Oncology, Inc. Common stock
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2024-01-25 | Chairman & CEO Mr. Arthur Kuan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://cgoncology.com |
Full time employees 113 | Website https://cgoncology.com | ||
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.